NOVARTIS AG (NVS)

Balfour Capital Group has issued a buy recommendation
for Novartis AG (NVS) on March 17 2023

Novartis AG, based in Basel, Switzerland, is a leading multinational pharmaceutical corporation. Formed in 1996 from the merger of Ciba-Geigy and Sandoz, Novartis produces drugs like Clozaril, Diovan, Gleevec, Ritalin, and Lamisil. It divested its agrochemical business in 2000, forming Syngenta.

Post Recommendation Price Trend Chart The chart's commencement marks the instance of our stock recommendation.

Analysts Research

With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.

Balfour-Capital

BALFOUR CAPITAL GROUP

Balfour Capital Group buy recommendation research

BALFOUR CAPITAL RECOMMENDATION

VIEW MORE
novartis

2024 Q1 EARNING REPORT

A Q1 report evaluates company financials for investors

EARNINGS REPORT

VIEW MORE

ARGUS QUANTITIVE

Argus Quantitative analyzes energy, commodities, and finance with data analytics

ARGUS QUANTITIVE

VIEW MORE

ARGUS ANALYST

Argus Analyst Notes offers timely investment recommendations, insights.

ARGUS ANALYST

VIEW MORE

Balfour Capital Group wants to clarify that our recommendation to Buy Novartis AG  (NVS) is based on thorough research conducted by our dedicated teams.

We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.

*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*